北京商报讯（记者 丁宁）8月15日晚间，思创医惠（300078）发布公告称，公司收到杭州市公安局出具 给公司的《调取证据通知书》。《调取证据通知书》显示，杭州市公安局侦办的公司等涉嫌欺诈发行证 券案需调取公司有关证据材料。 思创医惠表示，截至目前，上述案件尚处于公安机关侦查阶段，尚未有明确结论。公司将积极配合公安 机关的调查取证工作。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-086 思创医惠科技股份有限公司 关于募集资金专项账户全部注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"或"思创医惠"）于 2025 年 4 月 28 日召开了第六届董事会第五次会议和第六届监事会第五次会议，于 2025 年 7 月 30 日召开了 2025 年第三次临时股东会，分别审议通过了《关于终止募集 资金投资项目并将剩余募集资金永久补充流动资金的议案》，同意终止公司 2018 年度非公开发行股票项目（以下简称"非公开项目"）中的"物联网智慧医疗溯 源管理项目"和"医疗大数据应用研发中心"，同意终止公司 2020 年度向不特 定对象发行可转换公司债券项目（以下简称"可转债项目"）中的"互联网+人 工智能医疗创新运营服务项目""营销体系扩建项目"及"基于人工智能和微服 务云架构新一代智慧医疗应用研发项目"，并将剩余募集资金全部用于永久补充 流动资金。待募集资金投资项目终止并将剩余募集资金补充流动资金实施完毕后， 公司将授权管理层办理相 ...

截至目前，上述案件尚处于公安机关侦查阶段，尚未有明确结论。公司将积 极配合公安机关的调查取证工作。 思创医惠科技股份有限公司 证券代码：300078 证券简称：思创医惠 公告编号：2025-087 关于收到杭州市公安局调取证据通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 8 月 14 日，思创医惠科技股份有限公司（以下简称"公司"）收到 杭州市公安局出具给公司的《调取证据通知书》【杭公（经）调证字[2025]00481 号】。《调取证据通知书》显示，杭州市公安局侦办的公司等涉嫌欺诈发行证券 案需调取公司有关证据材料。 公司将根据本案件的进展情况及时履行信息披露义务。公司指定的信息披露 媒体是《证券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn），公 司所有信息均以在上述指定媒体披露的公告为准。敬请广大投资者关注相关公告 并注意投资风险。 特此公告。 思创医惠科技股份有限公司董事会 2025 年 8 月 15 日 ...

Core Insights - The DRG/DIP concept increased by 1.00%, ranking 10th among concept sectors, with 11 stocks rising, including Jiarun Technology which hit a 20% limit up [1] - Major gainers in the sector included Jiahe Meikang, Wanda Information, and Taiji Co., with respective increases of 3.68%, 3.08%, and 2.98% [1] - The sector experienced a net outflow of 229 million yuan, with 10 stocks seeing net inflows, and Wanda Information leading with a net inflow of 65.92 million yuan [2][3] Sector Performance - The top-performing concept sectors included Rare Earth Permanent Magnet (+3.24%), Brain-Computer Interface (+2.69%), and Hyperbaric Oxygen Chamber (+2.56%), while the weight-loss drug sector saw a decline of -1.70% [2] - The DRG/DIP concept had a net inflow ratio led by Wanda Information at 10.09%, followed by ST Yilianzhong at 5.78% and Taiji Co. at 4.82% [3][4] Stock Specifics - Key stocks in the DRG/DIP concept included: - Wanda Information: +3.08%, net inflow of 65.92 million yuan, turnover rate of 5.34% [3] - Weining Health: +1.72%, net inflow of 62.81 million yuan, turnover rate of 6.37% [3] - Taiji Co.: +2.98%, net inflow of 42.14 million yuan, turnover rate of 5.36% [3] - Notable declines were seen in stocks like Maidi Technology (-2.61%) and Seli Medical (-2.32%), with significant net outflows [4]

截至2025年8月5日收盘，思创医惠股价报4.07元，较前一交易日下跌0.06元，跌幅1.45%。当日成交量 为571102手，成交额达2.34亿元。 风险提示：投资有风险，入市需谨慎。 思创医惠属于互联网服务和物联网领域，是一家专注于医疗信息化和智能医疗设备研发的企业。公司主 要业务包括医疗信息化整体解决方案、智能开放平台、物联网技术应用等。 来源：金融界 8月5日公司公告显示，已完成向苍南县山海数字科技有限公司出售医惠科技有限公司100%股权的交 易，交易对价为3亿元。山海数科已支付全部款项，医惠科技已完成工商变更登记手续。2025年一季 度，思创医惠实现收入4.09亿元，归母净利润-1956万元。 资金流向方面，8月5日主力资金净流出1965.04万元，占流通市值比为0.43%。近五日主力资金净流入 1028.29万元，占流通市值比为0.23%。 ...

Core Viewpoint - The independent financial advisor, Guojin Securities, has issued a verification opinion regarding the major asset sale and related transactions of Sichuang Medical Technology Co., Ltd, confirming compliance with relevant laws and regulations [1][2]. Group 1: Transaction Overview - The transaction involves the sale of 100% equity of Yihui Technology Co., Ltd by Sichuang Medical Technology to Cangnan Mountain Sea Digital Technology Co., Ltd [3]. - The transaction price is based on the asset evaluation report, amounting to RMB 299.5995 million [4][5]. - The transaction constitutes a major asset restructuring as it meets the criteria set forth in the restructuring management regulations [5][6]. Group 2: Financial Assessment - The assessed value of the total equity of Yihui Technology is RMB 236.1515 million, with an increase rate of 26.87% compared to the book value of RMB 185.0000 million [4][5]. - The total assets of Sichuang Medical and Yihui Technology are RMB 259,233.76 million and RMB 180,665.28 million respectively, indicating a ratio of 69.69% [5]. Group 3: Approval and Compliance - The necessary approvals and authorizations for the transaction have been obtained, and there are no pending decision-making or approval processes [6][7]. - The transfer of the target assets has been completed, with the registration of the assets under the buyer's name finalized [6][7]. Group 4: Management Changes - There have been changes in the board of directors and management personnel of both Sichuang Medical and Yihui Technology following the transaction [8]. - The first major shareholder, Lu Nan, signed the share transfer agreement, resulting in Cangnan County Finance Bureau indirectly holding an 11.33% stake, thus becoming the actual controller of the company [5][6]. Group 5: Risk and Compliance - Throughout the transaction process, there have been no instances of the company's funds or assets being occupied by the major shareholder or related parties [9]. - All related agreements and commitments have been fulfilled without any violations, ensuring compliance with legal and regulatory requirements [9][10].

Group 1 - The core opinion of the article is that the legal opinion issued by Beijing Deheng (Hangzhou) Law Firm confirms the legality and compliance of the major asset sale and related transactions of Sichuang Medical Technology Co., Ltd [1][4][14] - The transaction involves the transfer of 100% equity of Yihui Technology by Sichuang Medical to Shanhai Digital for a total price of 299.5995 million yuan [5][10] - The payment for the transaction will be made in cash, with the entire amount to be paid before the completion of the asset transfer [6][10] Group 2 - The legal opinion states that the transaction has received necessary approvals and authorizations from the company's board and shareholders [8][10][14] - The transfer of ownership for the assets has been completed, and the relevant registration procedures have been carried out [11][14] - There are no significant discrepancies between the actual situation of the transaction and the previously disclosed information [11][14] Group 3 - The company has confirmed that there have been no changes in the board of directors, supervisors, or senior management personnel of either the listed company or the target company since the disclosure of the restructuring report [12][14] - The transaction does not involve the transfer of debts and liabilities of the target company, and there have been no instances of fund occupation or guarantees provided to related parties during the transaction process [13][14] - All parties involved in the transaction are fulfilling their commitments and agreements as per the signed equity transfer agreement [13][14]

思创医惠公告，公司向苍南县山海数字科技有限公司出售持有的医惠科技有限公司100%股权，交易对 价为3亿元。截至公告披露日，交易对方已支付全部股权转让价款，公司已收到全部款项，并完成标的 资产过户手续。医惠科技于2025年8月5日完成工商变更登记手续，取得新的营业执照。本次交易构成重 大资产重组和关联交易。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-085 思创医惠科技股份有限公司 关于重大资产出售暨关联交易实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）向苍南县山海数字科技有 限公司（以下简称"山海数科"）出售公司持有的医惠科技有限公司（以下简称 "医惠科技"或"标的公司"）100%股权，根据《上市公司重大资产重组管理办 法》（以下简称"《重组管理办法》"）的规定，上述交易事项构成重大资产重 组（以下简称"本次交易"）。根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）以及《深 圳证券交易所创业板股票上市规则》等法律、法规及规范性文件的相关规定，本 次交易构成关联交易。 公司分别于 2025 年 4 月 28 日、2025 年 5 月 29 日、2025 年 7 月 14 日、2025 年 7 月 30 日召开第六届董事会第五次会议、第六届董事会第七次会议、第六届 董事会第八次会议、2025 年第三次临时股东会，审议通过了与 ...

国金证券股份有限公司 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况 之 独立财务顾问核查意见 独立财务顾问 二零二五年八月 声明 国金证券股份有限公司接受思创医惠科技股份有限公司董事会的委托，担任 本次思创医惠科技股份有限公司重大资产重组之独立财务顾问。 根据《公司法》《证券法》《重组管理办法》《26 号准则》等法律法规的相 关规定，按照证券行业公认的业务规范，本着诚实守信、勤勉尽责的精神，遵循 独立、客观、公正的原则，在认真审阅相关资料并充分了解本次交易行为的基础 上，本独立财务顾问出具了本核查意见。 本核查意见所依据的文件、材料由本次交易相关各方提供，本次交易相关各 方已承诺所提供文件和材料真实、准确和完整，不存在虚假记载、误导性陈述或 者重大遗漏。本独立财务顾问不承担由此引起的任何风险责任。 本独立财务顾问未委托或授权其他任何机构或个人提供未在本核查意见中 列载的信息和对本核查意见做任何解释或说明。 本核查意见不构成对思创医惠科技股份有限公司的任何投资建议或意见，本 独立财务顾问对投资者根据本核查意见作出的投资决策可能产生的风险，不承担 任何责任。本独立财务顾问特别提请广大投资者认真阅 ...